4th Quarter - Report — PRIME THERAPEUTICS for PRIME THERAPEUTICS (2008)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm

PRIME THERAPEUTICS

Client

PRIME THERAPEUTICS

Income

—

Expenses

$50,000

Expense method

A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing	Filed	Amount	Counted
4th Quarter - Report (this page)	Jan 6, 2009	$50,000	Replaced
4th Quarter - Report	Jan 7, 2009	$50,000	Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

pharmaceuticals (HR 5629, HR 1038, s 1695), healthcare reform, health information technology and health information privacy (S 1693, HR 6357, HR 6898, HR 5442, S 1814), antitrust (HR 971), comparative effectiveness research, Medicare Part D

Lobbyist	Covered position, as disclosed
JERRY STEFFL	—

Contacted: Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 6898 (110th), H.R. 5442 (110th), H.R. 6357 (110th), H.R. 1038 (110th), H.R. 971 (110th), H.R. 5629 (110th)

Insurance INS

Lobbyist	Covered position, as disclosed
JERRY STEFFL	—

Contacted: Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 971 (110th), H.R. 6357 (110th), H.R. 1038 (110th), H.R. 6898 (110th), H.R. 5629 (110th), H.R. 5442 (110th)

Pharmacy PHA

Lobbyist	Covered position, as disclosed
JERRY STEFFL	—

Contacted: Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 5629 (110th), H.R. 971 (110th), H.R. 6357 (110th), H.R. 6898 (110th), H.R. 1038 (110th), H.R. 5442 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.